Anaptysbio ANAB
NASDAQ ANAB
$56.80 -0.66 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Anaptysbio (ANAB) Preferred Stock Liabilities (2016)

Anaptysbio's (ANAB) quarterly Preferred Stock Liabilities came in at $28.2 million in Q4 2016.

Analysis

Anaptysbio (ANAB) Preferred Stock Liabilities (2016) Analysis & Trends

Anaptysbio (ANAB) has 1 years of Preferred Stock Liabilities data on file, last reported at $28.2 million in Q4 2016.

  • Quarterly Preferred Stock Liabilities changed N/A year-over-year to $28.2 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $28.2 million (changed N/A YoY) and the FY2016 annual result came in at $28.2 million, changed N/A from the prior year.
  • Preferred Stock Liabilities held at $28.2 million in Q4 2016.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $28.2 million in Q4 2016 to a low of $28.2 million in Q4 2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Anaptysbio 1.62 Bn 1.34 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 40.69 Mn